Arcadia Resources, Inc. (AMEX:KAD)
About Arcadia Resources, Inc Arcadia Resources, Inc., together with its wholly owned subsidiaries, is a national provider of home care, medical staffing, and pharmacy services operating under the service mark Arcadia HealthCare. The Company operates in three business segments: Home Care/Medical Staffing Services (Services), Pharmacy and Catalog. The Company conducts its business from approximately 70 facilities located in 18 states. The Company operates pharmacies in Indiana, California and Minnesota and has customer service centers in Michigan and Indiana. On May 19, 2009, the Company completed the sale of its Home Health Equipment (HHE) business.
Statistics Symbol
KAD
Beta
0.44
Current Price
$0.29
Market Capitalization:
56.10M
52 week range
$0.26 - $0.83
Shares Outstanding
193.05M
Avg Volume
434,879.00
Float:
122.55M
Financials Arcadia Resources, Inc. (AMEX:KAD) generated the total revenue of $25.84 million for the latest quarter ended September 30th, 2010. However the company ended the net loss of $3.10 million resulting in loss of $0.02 per share for the respective quarter. The company’s total assets accumulate up to $30.01 million with highest proportion of fixed assets in its composition standing at $17.39 million. The company maintains the current ratio of 1.9 times depicting high short term liquidity position maintained by the Arcadia Resources Inc. Arcadia total liabilities stand at $47.70 million as on September 30th, 2010.
SCOLR Pharma Inc. (AMEX:DDD)
About SCOLR Pharma Inc. SCOLR Pharma, Inc. is a specialty pharmaceutical company that combines formulation experience and knowledge with its Controlled Delivery Technology (CDT) platforms to develop and commercialize prescription, over-the-counter (OTC), and nutritional products. The Company has developed multiple private label extended release nutritional products incorporating its formulation technology for commercialization in the United States and Canada. Its lead drug product candidate is a 12 hour extended release formulation of ibuprofen, an analgesic used for the treatment of pain, fever and inflammation.
Statistics Symbol
DDD
Beta:
1.69
Current Price
$0.33
Market Capitalization:
16.43M
52 week range
$0.25 - $1.40
Shares Outstanding
49.82M
Avg Volume
81,284.00
Float:
48.20M
Financials As per its latest financial statements ending September 30 th, 2010 SCOLR Pharma Inc. (AMEX:DDD) earned the total revenue of $0.12 million for the quarter. However the company couldn’t meet its operating expenses and ended with net loss of $0.87 million or loss of $0.02 per share for the respective quarter. The company’s total assets accumulate up to $4.47 million with highest proportion of current assets standing at $3.11 million. SCOLR Pharma Inc maintains a strong short term liquidity position with current ratio of 8.63 times. Total liabilities stand at $0.53 million as compared to the total equity of $4.47 million as on September 30th, 2010.
Rexahn Pharmaceuticals, Inc. (AMEX:RNN)
About Rexahn Pharmaceuticals, Inc. Rexahn Pharmaceuticals, Inc. (Rexahn) is a clinical stage biopharmaceutical company developing and seeking to deliver cures for cancer and disorders of the central nervous system (CNS) to patients worldwide. Rexahn’s pipeline features three drug candidates in Phase II clinical trials and seven or more other drug candidates in pre-clinical development. Rexahn has three clinical stage drug candidates: Archexin, Serdaxin, and Zoraxel. Archexin, is a inhibitor of the protein kinase Akt. Archexin is developed for five cancer indications (renal cell carcinoma (RCC), glioblastoma, ovarian cancer, stomach cancer and pancreatic cancer). Its products in the pre-clinical pipeline include RX-1792, RX-5902, RX-3117, RX-8243, RX-0201, RX-0047, RX-21101 and RX-21202.
Statistics Symbol
RNN
Beta:
1.43
Current Price
1.15
Market Capitalization:
96.36M
52 week range
$0.63 - $3.68
Shares Outstanding
83.79M
Avg Volume
425,605.00
Float:
54.89M
Financials As per its last financial statements ending September 30 th, 2010 Rexahn Pharmaceuticals, Inc. (AMEX:RNN) generated the total revenue of $0.02 million for the quarter ended. The company was not able to meet its operating expenses and ended in net loss of $2.32 million or loss of $0.03 per share for the quarter. The company’s total assets accumulate up to $18.29 million with highest proportion of current assets standing at $16.94 million as of September, 30 th, 2010. The current ratio for the company arrives at 12.6 times depicting that current assets are 12.6 times more than the company’s current liabilities. The company’s high short term liquidity position is also evident from the fact that its cash and cash equivalents of $15.83 million covers the current liabilities by 11.8 times.
DISCLAIMER DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS WEBSITE OR IN ONE OF OUR NEWSLETTERS.
We are not registered as a securities broker-dealer or an investment advisor either within the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice.
The information contained on our website or in any of our newsletters should be viewed as commercial advertisement and is not intended to be investment advice. Any information found on our website, or in any of our newsletters is not provided to any particular individual with a view toward their individual circumstances. The information contained on our website, and in any newsletter we distribute, is not an offer to buy or sell securities. We distribute opinions, comments, and information free of charge exclusively to individuals who wish to receive them.
Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company. An individual should never invest in the securities of any of the companies profiled based solely on information contained in our report. Individuals should assume that all information contained on our website or in one of our newsletters about profiled companies is not trustworthy unless verified by their own independent research.
Any individual who chooses to invest in any securities should do so with caution. Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested. Always research your own investments and consult with a registered investment adviser or licensed stock broker before investing.
This newsletter is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. ChartPoppers.com is a wholly-owned subsidiary of Seo Freisin, Inc.. While Seo Freisin has not been compensated for the distribution of this particular email, any future email regarding a specific company will be the result of an advertising and promotional campaign for which Seo Freisin, Inc. receives compensation. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this newsletter as the basis for any investment decision. Seo Freisin and its affiliates currently hold no shares in the profiled company.
Seo Freisin, Inc., and/or its affiliates will hold, buy, and sell securities in the companies profiled. When compensated in shares, all readers should be aware that it is our policy to liquidate all shares immediately. We reserve the right to buy or sell the shares of any the companies mentioned in any materials we produce at any time. This compensation constitues a conflict of interest as to our ability to remain objective in our communication regarding the profiled companies.
Information contained in our report will contain “forward looking statements” as defined under section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Subscribers are cautioned not to place undue reliance upon these forward looking statements. These forward looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated. Factors that could affect performance include, but are not limited to, those factors that are discussed in each profiled company’s most recent reports or registration statements filed with the SEC. You should consider these factors in evaluating the forward looking statements included in the report and not place undue reliance upon such statements.
We are committed to providing factual information on the companies that are profiled. However, we do not provide any assurance asto the accuracy or completeness of the information provided, including information regarding a profiled company’s plans or ability to effect any planned or proposed actions. We have no first-hand knowledge of any profiled company’s operations and thereforecannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so. Statistical information, dollar amounts, and market size data was provided by the subject company and related sources which we believe to be reliable.
To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in this report, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information).